Log in
Enquire now

List of Retrotope Inc. patents

List of Retrotope Inc. patents
List of EcoSynthetix patents
List of The Clorox Company patents
List of Sidense patents
List of awards received by Emerald Fennell
List of companies in Ankur Capital's investment portfolio
Patents where
Current Assignee
Name
is
Retrotope Inc.Retrotope Inc.
Name
Description
Patent Applicant
Current Assignee
Inventor
Patent Jurisdiction
Patent Number
Date of Patent
‌
US Patent 11447441 Site-specific isotopic labeling of 1,4-diene systems

Patent 11447441 was granted and assigned to Retrotope Inc. on September, 2022 by the United States Patent and Trademark Office.

Retrotope Inc.
Retrotope Inc.
Retrotope Inc.
Retrotope Inc.
United States Patent and Trademark Office
United States Patent and Trademark Office
11447441
September 20, 2022
‌
US Patent 11285125 Oxidative retinal diseases

Patent 11285125 was granted and assigned to Retrotope Inc. on March, 2022 by the United States Patent and Trademark Office.

Retrotope Inc.
Retrotope Inc.
Retrotope Inc.
Retrotope Inc.
United States Patent and Trademark Office
United States Patent and Trademark Office
11285125
March 29, 2022
‌
US Patent RE49238 Alleviating oxidative stress disorders with PUFA derivatives

Patent RE49238 was granted and assigned to Retrotope Inc. on October, 2022 by the United States Patent and Trademark Office.

Retrotope Inc.
Retrotope Inc.
Retrotope Inc.
Retrotope Inc.
United States Patent and Trademark Office
United States Patent and Trademark Office
RE49238
October 11, 2022
‌
US Patent 10577304 Site-specific isotopic labeling of 1,4-diene systems

Patent 10577304 was granted and assigned to Retrotope Inc. on March, 2020 by the United States Patent and Trademark Office.

Retrotope Inc.
Retrotope Inc.
Retrotope Inc.
Retrotope Inc.
United States Patent and Trademark Office
United States Patent and Trademark Office
10577304
March 3, 2020
‌
US Patent 11510888 Alleviating oxidative stress disorders with PUFA derivatives

Patent 11510888 was granted and assigned to Retrotope Inc. on November, 2022 by the United States Patent and Trademark Office.

Retrotope Inc.
Retrotope Inc.
Retrotope Inc.
Retrotope Inc.
United States Patent and Trademark Office
United States Patent and Trademark Office
11510888
November 29, 2022
‌
US Patent 10052299 Alleviating oxidative stress disorders with PUFA derivatives

Patent 10052299 was granted and assigned to Retrotope Inc. on August, 2018 by the United States Patent and Trademark Office.

Retrotope Inc.
Retrotope Inc.
United States Patent and Trademark Office
United States Patent and Trademark Office
10052299
August 21, 2018
‌
US Patent 10058522 Oxidative retinal diseases

Patent 10058522 was granted and assigned to Retrotope Inc. on August, 2018 by the United States Patent and Trademark Office.

Retrotope Inc.
Retrotope Inc.
United States Patent and Trademark Office
United States Patent and Trademark Office
10058522
August 28, 2018
‌
US Patent 10154983 Neurodegenerative disorders and muscle diseases implicating PUFAs

Patent 10154983 was granted and assigned to Retrotope Inc. on December, 2018 by the United States Patent and Trademark Office.

Retrotope Inc.
Retrotope Inc.
United States Patent and Trademark Office
United States Patent and Trademark Office
10154983
December 18, 2018
‌
US Patent 10058612 Impaired energy processing disorders and mitochondrial deficiency

Patent 10058612 was granted and assigned to Retrotope Inc. on August, 2018 by the United States Patent and Trademark Office.

Retrotope Inc.
Retrotope Inc.
United States Patent and Trademark Office
United States Patent and Trademark Office
10058612
August 28, 2018
‌
US Patent 10015979 Isotopically modified compounds and their use as food supplements

Patent 10015979 was granted and assigned to Retrotope Inc. on July, 2018 by the United States Patent and Trademark Office.

Retrotope Inc.
Retrotope Inc.
Retrotope Inc.
Retrotope Inc.
United States Patent and Trademark Office
United States Patent and Trademark Office
10015979
July 10, 2018
‌
US Patent 11510889 Methods for inhibiting the progression of neurodegenerative diseases

Retrotope Inc.
Retrotope Inc.
Retrotope Inc.
Retrotope Inc.
United States Patent and Trademark Office
United States Patent and Trademark Office
11510889
November 29, 2022
‌
US Patent 11351143 Methods of treating amyotrophic lateral sclerosis

Patent 11351143 was granted and assigned to Retrotope Inc. on June, 2022 by the United States Patent and Trademark Office.

Retrotope Inc.
Retrotope Inc.
Retrotope Inc.
Retrotope Inc.
United States Patent and Trademark Office
United States Patent and Trademark Office
11351143
June 7, 2022
‌
US Patent 11491130 Methods of treating amyotrophic lateral sclerosis

Patent 11491130 was granted and assigned to Retrotope Inc. on November, 2022 by the United States Patent and Trademark Office.

Retrotope Inc.
Retrotope Inc.
Retrotope Inc.
Retrotope Inc.
United States Patent and Trademark Office
United States Patent and Trademark Office
11491130
November 8, 2022
‌
US Patent 10730821 Site-specific isotopic labeling of 1,4-diene systems

Patent 10730821 was granted and assigned to Retrotope Inc. on August, 2020 by the United States Patent and Trademark Office.

Retrotope Inc.
Retrotope Inc.
Retrotope Inc.
Retrotope Inc.
United States Patent and Trademark Office
United States Patent and Trademark Office
10730821
August 4, 2020
‌
US Patent 11166930 Isotopically modified components and therapeutic uses thereof

Patent 11166930 was granted and assigned to Retrotope Inc. on November, 2021 by the United States Patent and Trademark Office.

Retrotope Inc.
Retrotope Inc.
Retrotope Inc.
Retrotope Inc.
United States Patent and Trademark Office
United States Patent and Trademark Office
11166930
November 9, 2021
‌
US Patent 11241409 Neurodegenerative disorders and muscle diseases implicating PUFAs

Patent 11241409 was granted and assigned to Retrotope Inc. on February, 2022 by the United States Patent and Trademark Office.

Retrotope Inc.
Retrotope Inc.
Retrotope Inc.
Retrotope Inc.
United States Patent and Trademark Office
United States Patent and Trademark Office
11241409
February 8, 2022
‌
US Patent 10154978 Disorders implicating PUFA oxidation

Patent 10154978 was granted and assigned to Retrotope Inc. on December, 2018 by the United States Patent and Trademark Office.

Retrotope Inc.
Retrotope Inc.
United States Patent and Trademark Office
United States Patent and Trademark Office
10154978
December 18, 2018
‌
US Patent 10029956 Therapies for cancer using isotopically substituted lysine

Patent 10029956 was granted and assigned to Retrotope Inc. on July, 2018 by the United States Patent and Trademark Office.

Retrotope Inc.
Retrotope Inc.
United States Patent and Trademark Office
United States Patent and Trademark Office
10029956
July 24, 2018
18 results
0 selected
18 results
0 selected
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us